Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science

UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), announced the publication of the study titled “Complete synthesis of the bicyclic ring of a mutacin analog with orthogonally protected lanthionine via solid-phase intracyclization” in volume 25, Issue 11 of the Journal of Peptide Science.

“We continue to advance our understanding of how to best manipulate and expand our lantibiotic library, particularly our new semi-synthetic homologs of Mutacin 1140, in order to create new ways of fighting antibiotic-resistant infections and expand to novel indications,” stated Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc. “This publication provides us with additional insight on how to expand our pipeline by chemical derivatization, which we hope ultimately may result in the development of compounds with entirely different properties and a broader spectrum of activity, to include Gram-negative infections.”

Learn more about Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science.